

Autism Spectrum Disorder Market Set for Significant Growth by 2034, According to DelveInsight

DelveInsight's Autism Spectrum Disorder Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

LAS VEGAS , NV, UNITED STATES, January 21, 2025 /EINPresswire.com/ -- DelveInsight's "Autism Spectrum Disorder Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Autism Spectrum Disorder, historical and forecasted epidemiology as well as the Autism Spectrum Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

To Know in detail about the Autism Spectrum Disorder market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: [Autism Spectrum Disorder Market Forecast](#)

Some of the key facts of the Autism Spectrum Disorder Market Report:

- The Autism Spectrum Disorder market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
- In January 2025, the FDA granted fast-track designation to SPG601, an investigational small molecule developed to treat individuals with Fragile X syndrome. SPG601, a large-conductance, calcium-activated potassium (BK) channel activator, works by correcting synaptic dysfunctions associated with core symptoms of Fragile X, marking a significant advancement in the treatment of this genetic disorder.
- In July 2024, Jaguar Gene Therapy received FDA clearance to administer JAG201, a gene replacement therapy for pediatric and adult patients with autism spectrum disorder (ASD) caused by a SHANK3 mutation or deletion, and Phelan-McDermid syndrome, in a Phase I clinical trial. This breakthrough has the potential to revolutionize treatment for ASD linked to genetic mutations.
- In July 2023, EarliTec Diagnostics announced that the FDA granted 510(k) authorization for its second-generation EarliPoint™ Evaluation for Autism Spectrum Disorder, designed for children aged 16-30 months old. This diagnostic tool aims to improve early detection and intervention for children at risk for ASD.
- The prevalence of autism spectrum disorder (ASD) is rising globally, with approximately 1 in 44 children in the US diagnosed with ASD, and around 700,000 people in the UK. In Germany, children aged 6-11 years show the highest prevalence, with about 6.0 per 1,000, while Japan

reports an adjusted ASD prevalence of around 3%, with a male-to-female ratio of 2.2:1.

- The current ASD market is dominated by leading pharmaceutical companies, such as Otsuka, Johnson & Johnson, and Flynn Pharma, with approved therapies like ABILIFY (aripiprazole), RISPERDAL (risperidone), and SLENYTO (prolonged-release melatonin), which are expected to see increased market share as interventions evolve.
- The ASD market size is projected to experience substantial growth in the coming years, driven by increasing awareness, early diagnosis, and the development of novel therapies aimed at treating and managing ASD.
- Emerging therapies for autism spectrum disorder include ML-004, RG7816, AB-2004, L1-79, and others.
- Key companies involved in the ASD space include Aardvark Therapeutics, Inc., Otsuka Pharmaceutical, H. Lundbeck A/S, Jazz Pharmaceuticals, MapLight Therapeutics, Vanda Pharmaceuticals, ACADIA Pharmaceuticals Inc., AbbVie, Axial Therapeutics, Inc., Hoffmann-La Roche, Yamo Pharmaceuticals LLC, and others.
- The ASD market is expected to grow rapidly, driven by increasing demand for innovative treatments, early diagnosis solutions, and genetic therapies that aim to improve the quality of life for those living with ASD.

Autism Spectrum Disorder Overview

Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by challenges in social communication and interaction, along with restricted or repetitive behaviors, interests, and activities. Symptoms typically manifest early in development and significantly impact daily functioning. While individual experiences vary, the core symptoms are grouped into two main categories: difficulties in social communication and interaction, and restricted or repetitive behaviors. Diagnosis involves comprehensive evaluations by a multidisciplinary team, which often includes a physician, psychologist, and specialists in fields such as speech and language pathology or occupational therapy. Current treatment options focus on managing core symptoms and include psychosocial therapies as well as approved pharmacological treatments like aripiprazole, risperidone, and SLENYTO.

Get a Free sample for the Autism Spectrum Disorder Market Report:

https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=jpr

Autism Spectrum Disorder Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Autism Spectrum Disorder Epidemiology Segmentation:

The Autism Spectrum Disorder market report proffers epidemiological analysis for the study

period 2020–2034 in the 7MM segmented into:

- Autism Spectrum Disorder market by countries
- Autism Spectrum Disorder market by therapies
- Autism Spectrum Disorder market by classes.

Download the report to understand which factors are driving Autism Spectrum Disorder epidemiology trends @ [Autism Spectrum Disorder Epidemiology Forecast](#)

Autism Spectrum Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the uptake rate of potential drugs recently launched in the Autism Spectrum Disorder market or expected to be launched during the study period. The analysis covers Autism Spectrum Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Autism Spectrum Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Autism Spectrum Disorder Therapies and Key Companies

- ML-004: MapLight Therapeutics
- RG7816 (alogabat/RO7017773): Hoffmann-La Roche
- AB-2004: Axial Therapeutics
- Racemetirosine - Yamo Pharmaceuticals

And others.

Autism Spectrum Disorder Market Strengths

- Growing awareness about Autism Spectrum Disorder (ASD) among parents, educators, and healthcare providers is leading to earlier diagnoses and better management of the condition, fostering market growth.
- Continued research and the development of new therapies, including gene therapies, small molecule drugs, and novel diagnostic tools, are enhancing treatment options and improving patient outcomes, driving market expansion.

Autism Spectrum Disorder Market Opportunities

- A significant opportunity exists in developing treatments for both pediatric and adult populations, as the prevalence of ASD spans across various age groups, especially with the increasing recognition of ASD in adults.
- The rise of innovative treatments such as gene therapies (e.g., JAG201) and digital health

solutions (e.g., EarliPoint™) for early detection and management of ASD presents new growth opportunities for market players.

Scope of the Autism Spectrum Disorder Market Report

- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Autism Spectrum Disorder Companies: Aardvark Therapeutics, Inc., Otsuka Pharmaceutical, H. Lundbeck A/S, Jazz Pharmaceuticals, MapLight Therapeutics, Vanda Pharmaceuticals, ACADIA Pharmaceuticals Inc., AbbVie, Axial Therapeutics, Inc., Hoffmann-La Roche, Yamo Pharmaceuticals LLC, and others.
- Key Autism Spectrum Disorder Therapies: ML-004, RG7816, AB-2004, L1-79, and others.
- Autism Spectrum Disorder Therapeutic Assessment: Autism Spectrum Disorder current marketed and Autism Spectrum Disorder emerging therapies
- Autism Spectrum Disorder Market Dynamics: Autism Spectrum Disorder market drivers and Autism Spectrum Disorder market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Autism Spectrum Disorder Unmet Needs, KOL's views, Analyst's views, Autism Spectrum Disorder Market Access and Reimbursement

To learn more about Autism Spectrum Disorder companies working in the treatment market, visit @ [Autism Spectrum Disorder Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Autism Spectrum Disorder Market Report Introduction
2. Executive Summary for Autism Spectrum Disorder
3. SWOT analysis of Autism Spectrum Disorder
4. Autism Spectrum Disorder Patient Share (%) Overview at a Glance
5. Autism Spectrum Disorder Market Overview at a Glance
6. Autism Spectrum Disorder Disease Background and Overview
7. Autism Spectrum Disorder Epidemiology and Patient Population
8. Country-Specific Patient Population of Autism Spectrum Disorder
9. Autism Spectrum Disorder Current Treatment and Medical Practices
10. Autism Spectrum Disorder Unmet Needs
11. Autism Spectrum Disorder Emerging Therapies
12. Autism Spectrum Disorder Market Outlook
13. Country-Wise Autism Spectrum Disorder Market Analysis (2020–2034)
14. Autism Spectrum Disorder Market Access and Reimbursement of Therapies
15. Autism Spectrum Disorder Market Drivers
16. Autism Spectrum Disorder Market Barriers
17. Autism Spectrum Disorder Appendix
18. Autism Spectrum Disorder Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Jatin Vimal

DelveInsight Business Research LLP

+1 469-945-7679

info@delveinsight.com

This press release can be viewed online at: <https://www.einpresswire.com/article/778912333>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.